Michael B. Maris

16.7k citations

173 papers · 11.0k indexed · 1 hit paper · h-index 50

Impact in

Hematology top 0.05%
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
Transplantation top 0.5%
- Renal Transplantation Outcomes and Treatments

Papers in

Hematology 130
- Hematopoietic Stem Cell Transplantation 89
- Acute Myeloid Leukemia Research 48
- Chronic Myeloid Leukemia Treatments 17
Transplantation 11

Co-authors: Rainer Storb Brenda M. Sandmaier David G. Maloney Barry E. Storer Mohamed L. Sorror Frédéric Baron Thomas R. Chauncey Peter A. McSweeney
Journals: Blood (61 papers)Journal of Clinical Oncology (24 papers)Biology of Blood and Marrow Transplantation (19 papers)British Journal of Haematology (10 papers)Leukemia (3 papers)
Partner nations: United States Germany South Africa

In The Last Decade

Michael B. Maris

170 papers receiving 10.9k citations

Hit Papers

align trajectories log scale

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT 2005 · 2.0k citations

Peers

Countries citing papers authored by Michael B. Maris

Since Specialization

Citations

This map shows the geographic impact of Michael B. Maris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael B. Maris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael B. Maris more than expected).

Fields of papers citing papers by Michael B. Maris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael B. Maris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael B. Maris. The network helps show where Michael B. Maris may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael B. Maris, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael B. Maris Line = papers co-authored together Michael B. Maris links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A dose optimization phase 1b/2 study evaluating mipletamig (formerly APVO436), a novel bispecific CD123 x CD3 ADAPTIRÒ molecule in combination therapy for the treatment of frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy Blood ·Justin M. Watts, Gautam Borthakur, Tara L. Lin, Nashat Gabrail, Kruti Patel, Yazan F. Madanat, Joshua F. Zeidner, Noor M. Khaskhely, Lynn Bonham, Michelle R. Nelson, Яна Сергеевна Житарь, MA Keqin, Sheriff Kandeh, A Majczak, Dirk Huebner, Michael B. Maris	2025	0
2	ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia Blood ·Matthew S. Davids, Saad S. Kenderian, Ian W. Flinn, Brian T. Hill, Michael B. Maris, Paolo Ghia, Michael Byrne, Nancy L. Bartlett, John M. Pagel, Yan Zheng, Javier Cuevas, Wangshu Zhang, J. Mohd-Azlan, Javier Pinilla‐Ibarz	2025	2
3	ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study Targeted Oncology ·Michael B. Maris, Gilles Salles, Won Seog Kim, Tae Min Kim, Roger M. Lyons, Martha Arellano, Reem Karmali, Gary J. Schiller, Elizabeth H. Cull, Camille N. Abboud, Connie Lee Batlevi, Ioannis Kagiampakis, Marlon C. Rebelatto, Young Lee, Lyndon C. Kirby, Fujun Wang, John Bothos, Danielle M. Townsley, Amir T. Fathi, Vincent Ribrag	2024	4
4	Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network Blood Advances ·Minoo Battiwalla, Michael Tees, Ian W. Flinn, Jeremy Pantin, Jesús G. Berdeja, Tara Gregory, Michael B. Maris, Vikas Bhushan, Estil Vance, John A. Mathews, Carlos Bachier, Paul Shaughnessy, Aravind Ramakrishnan, Shahbaz A. Malik, Shahram Mori, Casey Martin, 浩一郎菅田, Betsy Blunk, Charles F. LeMaistre, Navneet S. Majhail	2024	4
5	Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting PubMed ·Minoo Battiwalla, 俊介山口, Alexander Tomic, José C. Cruz, William B. Donnellan, M. Guan, Suman Kambhampati, Shahbaz A. Malik, Michael B. Maris, Marcello Rotta, Frank T. Slovick, Aravind Ramakrishnan, Vikas Bhushan, Lindsay E. Sears, Casey Martin, Alyssa Luedtke, Angela G. Junglen, Navneet S. Majhail, Charles F. LeMaistre	2024	1
6	A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma Cancer Research Communications ·L.Q. Chen, Jeffrey G. Supko, Michael B. Maris, Ian W. Flinn, André Goy, Anas Younes, Melissa C Clark, Adrian M. Senderowicz, Jean-Marc Tétaz, Gaurav Namdev, Gozde Colak, Patrick Trojer, Jeremy S. Abramson	2022	23
7	Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) at Nonuniversity Medical Centers (NMCs): Initial Results from the Outreach Study in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Transplantation and Cellular Therapy ·John E. Godwin, César O. Freytes, Michael B. Maris, Don A. Stevens, Daanish Hoda, Bassam Mattar, Juan Carlos Varela, Mohamad Cherry, James Essell, Jay Courtright, Suzanne Fanning, Habte Yimer, Nikolaus S. Trede, Isabel Ma Fernández Medina, James Lymp, Carlos Bachier	2021	1
8	Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors Blood ·Brian Kornblit, Barry E. Storer, Niels Smedegaard Andersen, Michael B. Maris, Thomas R. Chauncey, Effie W. Petersdorf, Ann E. Woolfrey, Mary E.D. Flowers, Rainer Storb, David G. Maloney, Brenda M. Sandmaier	2020	14
9	Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia American Journal of Hematology ·Ian W. Flinn, Mohamad Cherry, Michael B. Maris, Jeffrey Matous, Jesús G. Berdeja, Manish R. Patel	2019	33
10	Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML Blood ·Ronan Swords, Steven Coutré, Michael B. Maris, Joshua F. Zeidner, James M. Foran, José C. Cruz, Harry P. Erba, Jesús G. Berdeja, Wayne Tam, Saran Vardhanabhuti, Nitin Chandrashekhar Adgaonkar, Hélène M. Faessel, Ajeeta B. Dash, Farhad Sedarati, Mutembei Henry M'Ïkiugu, Douglas V. Faller, Michael R. Savona	2018	157
11	Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331) Blood ·Ian W. Flinn, John G. Gribben, Martin J.S. Dyer, William G. Wierda, Michael B. Maris, Richard R. Furman, Peter Hillmen, Jeffrey A. Jones, Swaminathan P. Iyer, Surai Jones, Yanwen Jiang, Daniela Soriano Pignataro, Kathryn Humphrey, Mehrdad Mobasher, Thomas J. Kipps	2017	14
12	Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML) Blood ·Ronan Swords, Steven Coutré, Michael B. Maris, Joshua F. Zeidner, James M. Foran, José C. Cruz, Harry P. Erba, Jesús G. Berdeja, Wayne Tam, Saran Vardhanabhuti, José Luis Rénique Caycho, Hélène M. Faessel, Ajeeta B. Dash, Farhad Sedarati, Bruce J. Dezube, Michael R. Savona	2016	7
13	Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning Journal of Clinical Oncology ·Mohamed L. Sorror, Barry E. Storer, Brenda M. Sandmaier, Michael B. Maris, Judith A. Shizuru, Richard T. Maziarz, Edward Agura, Thomas R. Chauncey, Michael A. Pulsipher, Peter A. McSweeney, James C. Wade, Benedetto Bruno, Amelia Langston, Jerald P. Radich, Dietger Niederwieser, Karl G. Blume, Rainer Storb, David G. Maloney	2008	182
14	Unrelated Donor Granulocyte Colony-Stimulating Factor–Mobilized Peripheral Blood Mononuclear Cell Transplantation after Nonmyeloablative Conditioning: The Effect of Postgrafting Mycophenolate Mofetil Dosing Biology of Blood and Marrow Transplantation ·Michael B. Maris, Brenda M. Sandmaier, Barry E. Storer, David G. Maloney, Judith A. Shizuru, Edward Agura, Fernández Sepúlveda, Michael A. Pulsipher, Richard T. Maziarz, Peter A. McSweeney, James C. Wade, Amelia Langston, Thomas R. Chauncey, Benedetto Bruno, Karl G. Blume, Rainer Storb	2006	75
15	Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors Journal of Clinical Oncology ·Ute Hegenbart, Dietger Niederwieser, Brenda M. Sandmaier, Michael B. Maris, Judith A. Shizuru, Hildegard Greinix, Catherine Cordonnier, Bernard Rio, Aloïs Gratwohl, Thoralf Lange, Haifa Kathrin Al‐Ali, Barry E. Storer, David G. Maloney, Peter A. McSweeney, Thomas R. Chauncey, K C Kim, Benedetto Bruno, Richard T. Maziarz, Finn Bo Petersen, Rainer Storb	2005	181
16	Hematopoietic cell transplantation (HCT)-specific-comorbidity index: A new tool for risk assessment before allogeneic HCT Biology of Blood and Marrow Transplantation ·Mohamed L. Sorror, Michael B. Maris, Rainer Storb, Frédéric Baron, Brenda M. Sandmaier, David G. Maloney, Xabier Etxaniz Erle	2005	199
17	Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT Blood ·Mohamed L. Sorror, Michael B. Maris, Rainer Storb, Frédéric Baron, Brenda M. Sandmaier, David G. Maloney, Barry E. Storer Hit paper breakdown →	2005	1977
18	Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation American Journal of Kidney Diseases ·Chirag R. Parikh, Robert W. Schrier, Barry E. Storer, Razvan Diaconescu, Mohamed L. Sorror, Michael B. Maris, David G. Maloney, Peter A. McSweeney, Rainer Storb, Brenda M. Sandmaier	2005	64
19	Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant Biology of Blood and Marrow Transplantation ·C.H. TAYLOR-ROBINSON, Brenda M. Sandmaier, David G. Maloney, Michael B. Maris, Theodore A. Gooley, Thomas R. Chauncey, Ute Hegenbart, Peter A. McSweeney, Monic J. Stuart, Stephen J. Forman, Edward Agura, Michael A. Pulsipher, Karl G. Blume, Dietger Niederwieser, Rainer Storb	2003	21
20	Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell response indicate a new phenotype in class II-deficient patients. The Journal of Experimental Medicine ·Ilona Hauber, Heinz Gulle, 猛吉成, Michael B. Maris, Ulas Biter, M Eibl	1995	37

About Michael B. Maris

Michael B. Maris is a scholar working on Hematology, Transplantation, Immunology, Genetics and Acoustics and Ultrasonics, having authored 173 papers that have together received 11.0k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (89 papers), Acute Myeloid Leukemia Research (48 papers), Immune Cell Function and Interaction (25 papers), Acute Lymphoblastic Leukemia research (25 papers), Chronic Lymphocytic Leukemia Research (22 papers), T-cell and B-cell Immunology (21 papers), CAR-T cell therapy research (18 papers) and Chronic Myeloid Leukemia Treatments (17 papers). The work is most often cited by research in Hematology (7.8k citations), Transplantation (848 citations), Genetics (1.6k citations), Immunology (2.5k citations) and Oncology (2.8k citations). Michael B. Maris has collaborated with scholars based in United States, Germany and South Africa. Frequent co-authors include Rainer Storb, Brenda M. Sandmaier, David G. Maloney, Barry E. Storer, Mohamed L. Sorror, Frédéric Baron, Thomas R. Chauncey, Peter A. McSweeney, Paul J. Martin and Michael A. Pulsipher. Their work appears in journals such as Blood, Journal of Clinical Oncology, Biology of Blood and Marrow Transplantation, British Journal of Haematology and Leukemia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact